Skip to content
Search

Latest Stories

Dr Reddy's enters UK consumer health market, launches allergy medication Histallay

Dr Reddy's enters UK consumer health market, launches allergy medication Histallay

People with hay fever can now get direct access to the product through pharmacies and supermarkets in the UK.  

Indian multinational pharmaceutical company, Dr. Reddy's Laboratories has made its entry into the UK consumer health market with the launch of an over-the-counter allergy medication.


Histallay (Fexofenadine Hydrochloride 120 mg tablets) is the company’s first general sale list (GSL) product introduced in the UK market.

Previously classified as a Prescription Only Medicine (POM), Dr. Reddy's Fexofenadine 120 mg is now available without prescription, under the brand name ‘Histallay’.

This allows people with allergic seasonal rhinitis (hay fever) to get direct access to the product via retail outlets such as pharmacies and supermarkets in the UK.

The Indian company said it is already one of the largest producers of Fexofenadine Hydrochloride ( the active pharmaceutical ingredient in Histallay), which is the most dispensed antihistamine in the UK.

“Entering consumer healthcare is a logical step for us and true to our purpose of offering more choices for customers and patients.

“Our expertise in the allergy segment has already allowed us to become a leader in the UK’s prescription fexofenadine market.

“By making Histallay available over the counter, we enable allergy sufferers to get faster access to treatment and better control over their symptoms since early treatment is key,” the company writes on its website.

Screenshot 2024 01 25 164551

What is Hay fever?

Hay fever, also called allergic rhinitis, is an allergic reaction commonly triggered by pollen, house dust mites, mould spores, and pet dander.

According to NHS, cases are higher between late March and September, when the pollen count is at its highest.

Hay fever causes cold-like symptoms, including a runny or blocked nose, sneezing and coughing, itchy eyes and throat, loss of smell, headache, earache, and tiredness.

For people with asthma, their symptoms may get worse when they have hay fever. They may experience a tight feeling in the chest, shortness of breath, wheezing, and cough.

While a cold usually goes away after 1 to 2 weeks, hay fever can last for weeks or months, the health service stated.

How to treat hay fever

Unfortunately, there's currently no cure for hay fever, but treatment can help relieve symptoms at least to a certain extent for most people.

Hay fever treatments include antihistamines (for preventing an allergic reaction) and corticosteroids or steroids (for reducing inflammation and swelling).

If you have hay fever, you can speak to your pharmacist, who can give you advice and suggest the best treatments.

The NHS advised people to see a doctor if their symptoms do not improve after taking medicines from the pharmacy and are getting worse.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less